Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Aura Biosciences, Inc.
13D/A
Amendment 4
AURA · 05153U107
|
0% |
5/11/2026
Event 5/7/2026
|
|||
| Matrix Capital Management Company LP | 0% | ||||
| David E. Goel | 0% | ||||
|
Zentalis Pharmaceuticals, Inc.
13D/A
Amendment 3
ZNTL · 98943L107
|
0% |
1/2/2026
Event 12/30/2025
|
|||
| Matrix Capital Management Company, LP | 0% | ||||
| David E. Goel | 0% | ||||
|
Zentalis Pharmaceuticals, Inc.
13D/A
Amendment 2
ZNTL · 98943L107
|
10.0% |
12/15/2025
Event 12/15/2025
|
|||
| Matrix Capital Management Company, LP | 10.0% | ||||
| David E. Goel | 10.0% | ||||
|
Maze Therapeutics, Inc.
13G/A
Amendment 1
MAZE · 578784100
|
3.5% |
11/13/2025
Event 9/30/2025
|
|||
| Matrix Capital Management Company, LP | 3.5% | ||||
| David E. Goel | 3.5% | ||||
|
Aura Biosciences, Inc.
13D/A
Amendment 3
AURA · 05153U107
|
11.2% |
5/19/2025
Event 5/16/2025
|
|||
| Matrix Capital Management Company LP | 11.2% | ||||
| David E. Goel | 11.2% | ||||
|
Maze Therapeutics, Inc.
13G
MAZE · 578784100
|
5.7% |
5/14/2025
Event 3/31/2025
|
|||
| Matrix Capital Management Company, LP | 5.7% | ||||
| David E. Goel | 5.7% | ||||
|
Altair Engineering Inc.
13G/A
Amendment 6
ALTR · 021369103
|
0% |
4/7/2025
Event 3/31/2025
|
|||
| Matrix Capital Management Company, LP | 0% | ||||
| David E. Goel | 0% | ||||
|
Perimeter Solutions, Inc.
13G/A
Amendment 2
PRM · 71385M107
|
4.5% |
2/12/2025
Event 12/31/2024
|
|||
| Matrix Capital Management Company LP | 4.5% | ||||
| David E. Goel | 4.5% | ||||
|
Adaptimmune Therapeutics plc
13G/A
Amendment 9
ADAPY · 00653A107
|
0% |
1/8/2025
Event 12/31/2024
|
|||
| Matrix Capital Management Company LP | 0% | ||||
| David E. Goel | 0% | ||||
|
Adaptimmune Therapeutics PLC
13G/A
Amendment 8
ADAPY · 00653A107
|
8.8% |
12/5/2024
Event 11/30/2024
|
|||
| Matrix Capital Management Company LP | 8.8% | ||||
| David E. Goel | 8.8% | ||||